APA (7th ed.) Citation

Schafer, E. S., Rau, R. E., Berg, S. L., Liu, X., Minard, C. G., Bishop, A. J., . . . Blaney, S. M. (2020). Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatric blood & cancer, 67(2), e28073-n/a. https://doi.org/10.1002/pbc.28073

Chicago Style (17th ed.) Citation

Schafer, Eric S., et al. "Phase 1/2 Trial of Talazoparib in Combination with Temozolomide in Children and Adolescents with Refractory/recurrent Solid Tumors Including Ewing Sarcoma: A Children's Oncology Group Phase 1 Consortium Study (ADVL1411)." Pediatric Blood & Cancer 67, no. 2 (2020): e28073-n/a. https://doi.org/10.1002/pbc.28073.

MLA (9th ed.) Citation

Schafer, Eric S., et al. "Phase 1/2 Trial of Talazoparib in Combination with Temozolomide in Children and Adolescents with Refractory/recurrent Solid Tumors Including Ewing Sarcoma: A Children's Oncology Group Phase 1 Consortium Study (ADVL1411)." Pediatric Blood & Cancer, vol. 67, no. 2, 2020, pp. e28073-n/a, https://doi.org/10.1002/pbc.28073.